[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Wooshin Labottach Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":102},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100642324","a-study-to-evaluate-the-safety-and-clinical-performance-of-a-dexpanthenol-medicated-hydrogel-patch-in-the-treatment-of-standardized-superficial-abrasions-100642324",false,"NCT07642973","A Study to Evaluate the Safety and Clinical Performance of a Dexpanthenol Medicated Hydrogel Patch in the Treatment of Standardized Superficial Abrasions","A Randomized, Single-Blind, Intra-Individual Controlled Study to Evaluate the Safety and Clinical Performance of a Dexpanthenol Medicated Hydrogel Patch in the Treatment of Standardized Superficial Abrasions","Dexpanthenol","Inclusion Criteria:\n\n* Healthy male or female volunteers aged 18 to 64 years (inclusive).\n* Informed consent form signed voluntarily before any study-related procedure.\n* Subjects willing and able to comply with all study protocol requirements, including scheduled visits and home-wear restrictions.\n* Intact, healthy skin on both volar forearms (free of tattoos, scars, sunburns, or active skin lesions in the designated test areas).\n* Agree to take precautions to prevent pregnancy (applicable only to non-menopausal women), including abstinence, intrauterine devices (IUDs), progestogen implants, combined estrogenic-progestogen contraceptives, the use of condoms;\n\nExclusion Criteria:\n\n* Known hypersensitivity or allergy to Dexpanthenol, hydrogel components, acrylic adhesives, or any component of the investigational devices.\n* History of keloid formation, hypertrophic scarring, or abnormal wound healing.\n* Active dermatological conditions (e.g., psoriasis, eczema, atopic dermatitis, active infections) on the upper extremities.\n* History of diabetes mellitus, peripheral vascular disease, or arterial\u002Fvenous microangiopathy.\n* Systemic treatment with corticosteroids, immunosuppressive drugs, Anticoagulants, antiplatelet agents or cytostatic agents within 4 weeks prior to Baseline, or anticipated need during the study.\n* Topical treatment (steroids, retinoids, antibiotics, or moisturizers) applied to the volar forearms within 2 weeks prior to Baseline.\n* Active heavy smokers (more than 10 cigarettes per day) or users of nicotine-replacement therapies (nicotine alters cutaneous microcirculation and significantly impairs wound healing kinetics)\n* Pregnant or lactating women, or women of childbearing potential not using highly effective contraception (see inclusion criteria).\n* Not willing and able to comply with all study protocol requirements",true,"ALL","18 Years","64 Years",{"count":22,"type":23},40,"ESTIMATED","INTERVENTIONAL",[26],"NA","Clinical evaluation of a Dexpanthenol-medicated wound plaster on standardized superficial skin abrasions",[29,30],"Skin Wounds","Abrasion",[32,33,34],"superficial wounds","dexpanthenol","plaster","NOT_YET_RECRUITING","2026-06-12",{"date":38,"type":39},"2026-06-16","ACTUAL",{"date":41,"type":23},"2026-09",{"date":43,"type":23},"2026-12",{"name":45,"class":46},"Wooshin Labottach Co., Ltd.","INDUSTRY",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":24,"phases":57,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":47},"100631496","clinical-trial-evaluating-the-efficacy-and-safety-of-uracil-05-plasters-in-oncology-patients-affected-by-hand-foot-syndrome-hfs-100631496","NCT07501442","Clinical Trial Evaluating the Efficacy and Safety of Uracil 0,5% Plasters in Oncology Patients Affected by Hand-foot Syndrome (HFS)","A Randomized, Single Blind, Parallel Groups, Clinical Trial Evaluating the Efficacy and Safety of Uracil 0,5%-Containing Plasters Versus \"Lenitive Cream\", in Oncology Patients Affected by Hand-foot Syndrome (HFS)","Inclusion Criteria\n\n* Both sexes;\n* Aged over 18 years;\n* Willing and able to return to the study site for post-procedural assessments;\n* Agree to take precautions to prevent pregnancy (applicable only to non-menopausal female subjects), including abstinence, intrauterine device (IUD), progestin implants, combined estrogen-progestin contraceptives, or condom use;\n* Agree to sign the informed consent form.\n* With HFS of grade I and II severity due to chemotherapy Self-sufficient with Performance Status of 0, 1, 2 according with the EOCG table.\n* Red blood cells folate test and serum folate test- Independent Biomarkers performed and to polymorphism testing DPD before starting therapy with dihydro pyrimidines.\n\nExclusion criteria\n\n* Patients with grade III severity according to of HFS severity (Hand-Foot Syndrome- NCI-CTCAE v.0 Severity Grading.\n* ECOG Performance Status Scale = 3 or 4\n* Pregnancy (applicable only to non-menopausal female subjects);\n* Breastfeeding (applicable only to non-menopausal female subjects);\n* Non-menopausal female subjects not using the specified contraceptive measures to prevent pregnancy during the study;\n* Sensitivity or allergy to the investigational product or its components (to be assessed by the investigator at baseline);\n* Predicted poor compliance with study protocol;\n* Participation in a similar study currently or within the past 3 months;\n* Dermatological clinical conditions that could interfere with performance outcomes;\n* Current pharmacological treatment with:\n\n  * Medications that may affect test results as deemed by the investigator.\n  * Use of other medications not mentioned above can be authorized by the investigator. Trade name, dosage, start and end dates of therapy will be documented in the concomitant medication form.",{"count":56,"type":23},80,[26],"The goal of this clinical trial is to learn if The Uracil plaster works to treat mild HFS in adults under chemiotherapy. It will also learn about the safety .\n\nThe main questions it aims to answer are:\n\nDoes Uracil Plaster lower the number of days participants need to reduce the HFS symptoms? What medical problems do participants have when using the Uracil plaster MD? Researchers will compare the Uracil plaster to a standard lenitive cream to see if Uracil Plaster works better to treat mild HFS.\n\nParticipants will:\n\nUse the plaster or the cream 2\u002F3 times day for 3 weeks Visit the hospital once every week for checkups and tests Keep a diary of their symptoms and the number of times they use the therapy",[60],"HFS",[62,63,60,64],"Uracil","uracil plaster","HFS in oncologic patients","2026-03-25",{"date":67,"type":39},"2026-03-30",{"date":69,"type":23},"2026-07",{"date":71,"type":23},"2027-04",{"name":45,"class":46},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":24,"phases":82,"briefSummary":84,"conditions":85,"keywords":89,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":101,"locationsCount":47},"100595212","phase-3-study-to-assess-efficacy-safety-and-tolerability-of-a-nail-patch-in-patients-with-nail-fragility-mychosis-psoriasis-100595212","NCT07029516","Study to Assess Efficacy, Safety and Tolerability of a Nail Patch in Patients With Nail Fragility, Mychosis, Psoriasis","A Randomized, Double Blind, Placebo-controlled, Unicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of a Multi-funtion Toe Nail Patch in Patients Affected by Nail Fragility, Nail Mychosis and Psoriasis","Inclusion Criteria:\n\n* aged 18 years or older Fragility Nails Distal Subungual Onychomycosis Nail Psoriasis affecting ≤75% of the nail bed according to a photographic documentation and to a subjective evaluation by the Investigator.\n\nExclusion Criteria:\n\n* Patients that have proximal subungual onychomycosis, if their distal subungual onychomycosis is extended into the proximal portion of the nail or if it affects \\>75% of the nail.\n* Patients with conditions known to cause abnormal nail appearance, immunosuppression and signs of severe peripheral circulatory insufficiency\n* Patients who had used topical antifungal, anti-psoriasis nail treatment within one month or systemic antifungal treatment within three months.\n* Patients who have participated in another clinical nail study during the previous three months\n* Patients who have a known allergy to any of the study treatments.\n* Patients with unrelated nail disorders: onychomycosis, nail psoriasis, genetically induced onychodystrophy.\n* Patients with other nail disorders, active or severe psoriasis elsewhere, other autoimmune or inflammatory diseases.",{"count":81,"type":23},72,[83],"PHASE3","A randomized, double blind, placebo-controlled, unicenter, parallel group study to assess the efficacy, safety and tolerability of a multi-funtion toe nail patch in patients affected by nail fragility, nail mychosis and psoriasis 72 patients in 6 subgroups Treatment duration 3 months + 1 month follow-up",[86,87,88],"Nail Psoriasis","Nail Damage","Mycosis",[90,91,92,93],"ONICOMYCOSIS","PATCH","UREA","PSORIASIS","RECRUITING","2026-01-22",{"date":97,"type":39},"2026-01-26",{"date":99,"type":23},"2026-02",{"date":43,"type":23},{"name":45,"class":46},""]